Immunoglobulin G antibody to human cytomegalovirus (CMV)-specific early antigens (EA-Ab) was determined by the immunoperoxidase antibody technique in several cases of congenital, primary, and reactivated CMV infections. Mothers of congenitally infected infants and a group of leukemic children and pregnant women were also studied. In 11 cases of congenital infection, CMV EA-Ab was always associated with CMV excretion whether immunoglobulin M antibody was present or not. Nine mothers of congenitally infected infants had CMV EA-Ab for several months after delivery, but association with CMV elimination was not established when urine and/or saliva were tested for virus isolation. In all nine cases of primary CMV infection, CMV EA-Ab was present, and in five its detection was associated with CMV isolation. In one case, disappearance of EAAb occurred when virus excretion ceased. In five cases of reactivated CMV infections, a consistent association between CMV EA-Ab and virus isolation was found. Six of 31 leukemia children had CMV EA-Ab, and virus was isolated from 3 of these. Four of 28 pregnant women showed EA-Ab in their serum, but tests for isolation were not done. These data suggest that CMV EA-Ab is not a marker of a current primary CMV infection, as previously reported, but a marker of an active CMV replication which can take place in primary as well as in congenital and reactivated CMV infections.
Determination of antibody to early antigens of Epstein-Barr virus in human sera has been reported and its significance defined (9) . Using the indirect fluorescent antibody (IFA) technique, The et al. (19) were the first to study the behavior of antibodies to human cytomegalovirus (CMV) early antigens (EA-Ab) in cases of primary CMV infections (most of which followed the administration of several fresh blood units). The presence of CMV EA-Ab was then reported in individuals receiving CMV experimental vaccine (15) and in women excreting CMV in cervical secretions (21) . However, the real meaning and practical importance of this type of antibody have not been clarified. In the present report, we used the indirect immunoperoxidase antibody technique (IPA) to study the behavior of CMV EA-Ab in several cases of congenital, primary, and reactivated CMV infections. Furthermore, since leukemia (2, 18) and pregnancy (13, 14, 16) are both known as possible sources of latent CMV infection reactivation, CMV EA-Ab was searched for in a group of children suffering from acute lymphocytic leukemia and in a group of pregnant women. Results show that CMV EAAb is consistently detectable in patients from whom CMV is isolated. In a minor number of cases the presence of EA-Ab is not associated with virus isolation, but active CMV replication and excretion cannot (6) . The application of sera and conjugate for CMV EA-Ab determination followed the same steps previously described for IgG detection (5) .
Reference sera. Sera drawn from two patients with CMV mononucleosis 3 to 4 weeks after the onset of the infection were used as CMV EA-Ab-positive serum control. Sera from two healthy blood donors were used as EA-Ab-negative IgG-positive serum control.
IHA test. Indirect hemagglutination (IHA) reagent preparation and test were performed according to the procedure of Bernstein and Stewart (1) for detection of broad-spectrum CMV antibody (LAb). MA-184 cell cultures were used for antigen preparation.
IgM determination on serum fractions. Serum fractionation was performed by sucrose density gradient centrifugation following the modification recommended by the Center for Disease Control (Atlanta, Ga.) of a previous procedure (20) . On the same day that serum fractions were collected, unfractionated sera as well as fractions of each serum were tested by IHA for IgM and IgG detection. Simultaneously, fractions were tested for the presence of IgM, IgG, and IgA using radial immunodiffusion plates (BehringWerke AG, Marburg/Lahn, W. Germany). Furthermore, when specific antibody activity was found in fractions 2 to 4, tests for low levels of IgG were performed by radial immunodiffusion.
CMV isolation and identification. CMV isolation was carried out on MRC-5 (Flow Laboratories, Irvine, Scotland) and MA-184 cell cultures, and identification was achieved using an IPA technique as previously reported (6) .
Subjects and patients examined. The following groups of subjects and patients were examined for determination of CMV IHA antibody titer, IPA-IgG, IHA-IgM on serum fractions, and EA-Ab: (i) 9 cases of primary CMV infection; (ii) 11 infants with congenital infection; (iii) 5 
RESULTS
Patterns of IPA staining of cells containing CMV EA-Ab with reference sera. Control serum drawn during the convalescent phase of MCV mononucleosis (CMV EA-Ab-and IgGpositive) produced a strong fine granular staining of the entire nucleus of cytosine arabinosidetreated CMV-infected cells, whereas the intensity of the cytoplasmic staining ranged from absent to faint. Selected CMV-positive and CMV-negative sera from blood donors (EA-Ab negative) did not stain either the nucleus or the cytoplasm of the cytosine arabinoside-treated cells (Fig. 1) . Staining patterns of CMV-infected cells used as a substrate for CMV IgG and IgM determination by the IPA technique have been previously described (4).
Primary infections. Of nine cases of primary CMV infection, six were CMV mononucleosis and one was associated with myopericarditis, one with cerebral atrophy, and one with respiratory symptoms ( Fig. 2 and Table 1 ). In all cases, CMV-specific IgM antibody and EA-Ab were detected in serum. In five cases CMV EAAb was associated with virus isolation; in three cases CMV was not recovered from urine and/or saliva; and in one, specimens for isolation were not available. However, in the last four cases CMV EA-Ab was also found at a high titer. Figure 2 reports titers of three cases followed for several weeks. In the first case (G.S.), EA-Ab disappeared when virus excretion ceased, but reappeared with reactivation of CMV infection. In the second case (a patient suffering from myopericarditis, D.D.P.D.), a clear tendency of EA-Ab to decrease in titer 11 weeks after the onset of infection (even in the presence of continuous CMV excretion) was followed by a new peak in parallel with a relapse of the cardiac infection. During the entire 6-month period of EA-Ab titer was observed. However, EA-Ab titers were usually lower than XAb titers. In nine cases, mother's serum samples were available for testing, and in all nine CMV EA-Ab was detected even more than 10 weeks after delivery. However, in a restricted number of cases, where mother's specimens were submitted for isolation, CMV was not recovered from urine and/or saliva. In the three cases where multiple sequential mother's serum samples were available, a slow fall in CMV EA-Ab titer was observed (F.A., A.G., and P.S., mothers; Fig. 3 serum sample was drawn. In the other two cases, CMV was not isolated, but specimens for isolation were available only a few months later.
In the group of 31 leukemic children, EA-Ab was present in 6 cases and CMV was isolated from 3 of these. In the group of 28 pregnant women, CMV EA-Ab was detected in 4 (Table  4 ). All four were in the second or third trimester of pregnancy. Unfortunately, in this group, specimens for isolation were not available. DISCUSSION The first report studying the behavior of CMV EA-Ab in patients with CMV infection stated that the presence of this type of antibody in an acute-phase serum at a titer of 1:80 can be taken as suggestive of a current primary infection (19) . However, this study did not establish any relationship between the presence of CMV EA-Ab and CMV excretion and between EA-Ab and CMV infections other than primary (i.e., congenital or reactivated). The data reported in the present paper appear to emphasize a close correlation between the presence of CMV EA-Ab and an active virus replication, and show that CMV EA-Ab is present in primary as well as in congenital and reactivated CMV infections, whether IgM antibody is detectable or lacking. The suggested relationship between different types of CMV infection and different types of CMV antibody response (LAb, IgM, and EAAb) is reported in Table 5 .
The data of The et al. (19) in primary infections are here confirmed, but the presence of CMV EA-Ab is also related to CMV excretion and CMV-specific IgM antibody. The presence of EA-Ab does not correlate with the detection of IgM antibody but appears to correlate well with an active CMV replication and excretion. This seems to be confirmed by case G.S. (Fig.  2) , where EA-bA disappeared when virus excretion stopped and reappeared when virus elimination started again. The absolute titer of CMV EA-Ab alone does not seem to be significant as far as diagnosis of a current primary CMV infection is concerned. Titers of 21:64 were found in primary as well as in congenital and reactivated CMV infections. The time of appearance of CMV EA-Ab seems to be within the first week after the onset of symptoms (case M.M., Fig. 2) . In a study of varicella-zoster EA-Ab during the acute phase of varicella, we found that this antibody appears 2 to 3 days later than IgG antibody, but always within a week after the onset of the exanthem (manuscript in preparation).
In congenitally infected infants the association between the presence of CMV EA-Ab and CMV excretion was observed in all cases studied, even when tests were performed 11 years after birth. In these cases, CMV IgM antibody was never detected more than 16 weeks after birth. In the group of mothers of infants with congenital CMV infection, EA-Ab was, in all cases, detectable for at least several months after delivery. However, in a few instances where specimens for virus isolation were available (urine and/or saliva), virus was not recovered. CMV isolation from urine and cervical secretions of mothers of congenitally infected infants has been reported for several months or a few years after delivery, progressive fall in titer.
In the group of five reactivated CMV infections, CMV elimination was always associated with detection of EA-Ab at different titers. In the three groups of subjects (healthy people, leukemic children, and pregnant women) tested for presence of CMV EA-Ab, the prevalence of this antibody was 6 of 31 leukemic children, 4 of 28 pregnant women, and 3 of 17 healthy people.
CMV was isolated from 4 of these 13 EA-Abpositive individuals, but only 9 were tested for virus isolation. It may be of some interest that all three healthy subjects positive for CMV EAAb had a CMV antibody titer of 21:1,024.
Whether, in healthy people, an elevated CMV antibody titer could be associated with a higher prevalence of CMV EA-Ab remains to be investigated in further studies. We believe that the finding of CMV EA-Ab is not unusual in people considered healthy and is possibly a marker of an active CMV replication. Thus, our data do not add evidence to the finding that acute lymphocytic leukemia (2, 18) and pregnancy (13, 14, 16) may increase the CMV infection reactivation rate.
The appearance of CMV EA-Ab in two of four CMV-seronegative subjects receiving a live attenuated CMV vaccine has been reported, but virus excretion was never detected (15) . Only three out of eight women eliminating virus with (21) and in 57 sera from healthy people or from patients with infections of different etiology (19) .
In our study, all patients excreting CMV showed the presence of EA-Ab in serum, whereas in some subjects the presence of EA-Ab was not associated with virus excretion. In these cases the lack of virus isolation might be due to several reasons: (i) CMV replication could occur without detectable virus excretion; (ii) CMV excretion is intermittent (7); or (iii) CMV excretion can occur from one site but not from another; thus virus excretion with semen (11, 12) , tears (3), breast milk (8) , and cervical secretions (13, 14, 16) could occur in people with EA-Ab who are not eliminating virus with urine and saliva (specimens routinely tested). Although we cannot conclusively rule out that EA-Ab may be detectable also in the absence of CMV excretion, we believe that CMV EA-Ab determination might be useful for the detection of an active CMV infection.
The IPA technique used in the present study for CMV EA-Ab determination presents several well-known advantages (10) over the IFA technique used by others (15, 19, 21) .
